571189-49-6

Basic information

• Product Name: 1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE
• Synonyms: 1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE;2-PyridinaMine, 5-(4-Methyl-1-piperazinyl)-;5-(4-Methyl-piperazin-1-yl)-pyridin-2-ylamine;5-(4-Methylpiperazin-1-yl)
• CAS NO: 571189-49-6
• Molecular Formula: C₁₀H₁₆N₄
• Molecular Weight: 192.27
• Mol File: 571189-49-6.mol
• Article Data: 51

Chemical Properties

• Melting Point: 148 °C
• Boiling Point: 368.115 °C at 760 mmHg
• Flash Point: 176.43 °C
• Appearance: /
• Density: 1.143 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 7.41±0.42(Predicted)
• CAS DataBase Reference: 1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE(571189-49-6)
• EPA Substance Registry System: 1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE(571189-49-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 571189-49-6(Hazardous Substances Data)

Usage

Description

1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE, also known as 5-(4-Methylpiperazin-1-yl)pyridin-2-amine, is an organic compound with a unique chemical structure that features a methyl group, a piperazine ring, and an aminopyridinyl group. 1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE has potential applications in various industries due to its specific chemical properties and reactivity.

Uses

Used in Chemical Mechanical Planarization (CMP) Industry:
1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE is used as a chemical additive for CMP processes, specifically for tungsten-containing substrates. Its application reason is to enhance the planarization efficiency and improve the overall quality of the substrate surface, which is crucial for the performance of semiconductor devices and other microelectronic components.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 52092-47-4 5-chloro-2-nitropyridine 
• 1072-97-5 5-bromo-2-pyridylamine 
• 20511-12-0 2-amino-5-iodopyridine 
• 39856-50-3 5-bromo2-nitropyridine 
• 657410-79-2 1-methyl-4-(6-nitro-pyridin-3-yl)-piperazine 
• 53939-30-3 5-bromo-2-chloropyridine 
• 779345-37-8 5-fluoro-2-nitro-pyridine 

Downstream Products

• 1353553-11-3 N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)-4-(3-nitrophenoxy)thieno[3,2-d]pyrimidin-2-amine 
• 1346670-46-9 2-(5-fluoro-2-(hydroxymethyl)-3-(1-methyl-5-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1346671-95-1 4-fluoro-2-(1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1346669-62-2 2-(2-(hydroxymethyl)-3-(1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridine-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1346672-82-9 acetic acid 2-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-6-(1-oxo-3,4,6,7,8,9-hexahydro-1H-pyrazino[1,2-a]indol-2-yl)benzyl ester 
• 1242156-62-2 1-methyl-3-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyridin-2-one 
• 1349074-17-4 N-(1-methylethyl)-2-[(5-methyl-2-{[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino}-4-pyrimidinyl)amino]benzamide 
• 1178884-45-1 5-bromo-1-methyl-3-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyridin-2(1H)-one 
• 943747-42-0 (4Z)-6-bromo-4-({[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino}methylene)isoquinoline-1,3(2H,4H)-dione 

Relevant articles and documents

Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors

FMS-like tyrosine kinase-3 (FLT3) and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have been proven to play a significant role in tumor therapy. Herein, based on the previously reported JAK2/FLT3 inhibitor 18e, we described the synthesis, structure–activity relationship and biological evaluation of a series of unique 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives that inhibited FLT3 and CDK4 kinases. The optimized compound 23k exhibited low nanomolar range activities with IC50 values of 11 and 7 nM for FLT3 and CDK4, respectively. In the MV4-11 xenograft tumor model, the tumor growth inhibition rate of 23k dosed at 200 mg/kg was 67%, suggesting that 23k possessed an antitumor therapeutic effect.

FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS

The disclosure provides compounds of formula (I), or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.

Pyrimidine-2, 4-diamine compound and preparation method and application thereof

The invention discloses a pyrimidine-2, 4-diamine compound and a preparation method and application thereof, and relates to the technical field of medicinal chemistry, the pyrimidine-2, 4-diamine compound can be used for biological or pharmacological phenomena, cathepsin C participated signal channel conduction research, and evaluation of a novel cathepsin C inhibitor; in addition, through in-vitro and in-vivo anti-cathepsin C activity screening, the results show that the compound has relatively strong inhibitory activity on cathepsin C; through in-vivo anti-neutrophil serine protease activity screening, the result shows that the compound has relatively strong inhibitory activity on neutrophil serine protease; in-vivo anti-inflammatory activity screening results show that the compound has an effective treatment effect on an inflammatory disease model; meanwhile, the toxicity is low, and the application prospect is good.